ㅤNews
Momentum is building in the Vaccines Against Schistosomiasis for Africa project (VASA)
On August 18 2023, the kickoff investigator meeting for a crucial Phase 1b clinical trial for the Schistoshield® schistosomiasis vaccine took place in the Madagascar Institute for Vaccine Research (MIVR), with partners from the Groupe de Recherche Action Santé (GRAS) in Burkina Faso, the International Vaccine Institute, the University of Cambridge, and Pharmalys. Over half the population of Madagascar (52.1%) is affected by Schistosomiasis, with 107…
Release of new WHO guidelines on control and elimination of human schistosomiasis
WHO provides a new guideline on control and elimination of human schistosomiasis. The goal of this guideline is to provide evidence-based recommendations to countries in their efforts to accomplish schistosomiasis morbidity control and elimination as a public health problem, and to move towards interruption of transmission. Please find more details and the WHO guideline at: https://www.who.int/publications/i/item/9789240041608
Continue Reading Release of new WHO guidelines on control and elimination of human schistosomiasis
News of SchistoShield Phase 1a study initiation
Participant in Kaiser Permanente Washington Health Research Institute (KPWHRI) trial, based in Seattle, received the first injection of the SchistoShield vaccine on May 23, 2022. Participants include healthy people ages 18 through 55 years old, and assigned to different study groups based on when they enroll in the study. The trial assess the safety of the…
Continue Reading News of SchistoShield Phase 1a study initiation
VASA International Stakeholder Meeting in Ouagadougou
The Vaccines Against Schistosomiasis for Africa (VASA) consortium and the International Institute of Science and Technology (IIS Tech) co-hosted the first International Symposium on Tropical Diseases on November 24-26, 2022 in Ouagadougou Burkina Faso. The theme of this meeting was “Technological innovations and the fight against tropical diseases”, and included special highlighted sessions on the…
Continue Reading VASA International Stakeholder Meeting in Ouagadougou
VASA General Assembly Meeting
Vaccine Against Schistosomiasis for Africa (VASA) project consortium held an annual General Assembly Meeting on 27 January 2022. On a yearly basis, members from the VASA project consortium are gathered to exchange the achievements and current status of ongoing Work Packages including the clinical trials, sero-epidemiology studies, health economics studies, and human challenge trial, as…
Burkina Faso site pre-assessment visit
UCAM-IVI 1st pre-site assessment visit in Ouagadougou, Burkina Faso was conducted on 26-29 November 2019. During the visit, a group of members from the University of Cambridge and International Vaccine Institute visited the Groupe de Recherche Action en Santé (GRAS) and University of Ouagadougou for discussing the Phase I clinical trial and sero-epidemiology study.
ㅤMedia and Publication
This Project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement (No.815643)